Efficacy and safety of sintilimab plus anlotinib for PD-L1–positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase ii trial

Simple item page
dc.contributor.authorXu, Qin
dc.contributor.authorWang, Junjie
dc.contributor.authorSun, Yang
dc.contributor.authorLin, Yibin
dc.contributor.authorLiu, Jing
dc.contributor.authorZhuo, Yanhong
dc.contributor.authorHuang, Zhangzhou
dc.contributor.authorHuang, Songhua
dc.contributor.authorChen, Ying
dc.contributor.authorChen, Li
dc.contributor.authorKe, Meifang
dc.contributor.authorLi, Li
dc.contributor.authorLi, Zirong
dc.contributor.authorPan, Junping
dc.contributor.authorSong, Yanwen
dc.contributor.authorLiu, Rongqiang
dc.contributor.authorChen, Chuanben
dc.date.accessioned2023-03-14T05:23:18Z
dc.date.available2023-03-14T05:23:18Z
dc.date.issued2022-02-22
dc.description.abstractPURPOSE: No combined immunotherapy and antiangiogenic therapy have been investigated in exclusively programmed death-ligand 1 (PD-L1)–positive advanced cervical cancer (CA). We investigated the efficacy and safety of sintilimab plus anlotinib as second-line or later therapy for PD-L1–positive recurrent or metastatic (R/M) CA. PATIENTS AND METHODS: Patients with PD-L1–positive (Combined Positive Score ≥ 1) R/M CA who progressed after at least one prior systemic chemotherapeutic regimen or could not tolerate chemotherapy were eligible for the phase II trial. The patients received 200 mg sintilimab once on day 1 and 10 mg anlotinib once daily on days 1-14 every 3 weeks. The primary end point was investigator-confirmed objective response rate (ORR) per RECIST v1.1. Secondary end points included progression-free survival (PFS), overall survival, and disease control rate. Biomarkers were explored. RESULTS: Forty-two patients were enrolled. The ORR was 54.8% (95% CI, 38.7 to 70.2). In 39 efficacy-evaluable patients, the ORR was 59.0% (95% CI, 42.1 to 74.4); the disease control rate was 94.9% (95% CI, 82.7 to 99.4). The median PFS was 9.4 months (95% CI, 8.0 to 14.6). The median overall survival was not reached. Furthermore, 85.8% of the patients experienced treatment-related adverse events. The most frequent treatment-related adverse events were hypothyroidism (33.3%), elevated aspartate aminotransferase levels (21.4%), and hypertension (19.0%). Patients with altered PIK3CA, PI3K-AKT signaling, or KMT2D had a higher ORR, whereas those with altered STK11 and/or JAK2 had a significantly shorter PFS. CONCLUSION: Sintilimab plus anlotinib as second-line or later therapy is efficacious and safe for patients with advanced CA who have failed prior chemotherapy.en_US
dc.identifier.citationXu, Q., Wang, J., Sun, Y., Lin, Y., Liu, J., Zhuo, Y., Huang, Z., Huang, S., Chen, Y., Chen, L., Ke, M., Li, L., Li, Z., Pan, J., Song, Y., Liu, R., & Chen, C. (2022). Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(16), 1795–1805. https://doi.org/10.1200/JCO.21.02091en_US
dc.identifier.otherDOI: 10.1200/JCO.21.02091
dc.identifier.urihttps://hdl.handle.net/20.500.14041/6142
dc.language.isoen_USen_US
dc.publisherJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncologyen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectEfficacy and Safetyen_US
dc.subjectSintilimab Plus Anlotiniben_US
dc.subjectPD-L1–Positive Recurrenten_US
dc.subjectMetastatic Cervical Canceren_US
dc.titleEfficacy and safety of sintilimab plus anlotinib for PD-L1–positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase ii trialen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
jco-40-1795.pdf
Size:
514.87 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.65 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
SRHR Evidence (Best practice, Systematic reviews)